Paclitaxel and Concurrent Radiation in Upper Gastrointestinal Cancers

References

• Choy H., Rodriguez F. F., Koester S., Kilsenbeck S., Von Hoff D. D. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71: 3774–3778
   PubMed Web of Science ®Google Scholar
• Gupta N., Hu L. J., Deen D. F. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37: 885–895
   PubMed Web of Science ®Google Scholar
• Sinclair W. K., Morton R. A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res. 1996; 29: 450–474
   Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Fisher J., Teague D., Mitchell J. B. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 1994; 86: 441–446
   PubMed Web of Science ®Google Scholar
• Minarik L., Hall E. J. Taxol in combination with acute and low dose rate irradiation. Radiother. Oncol. 1994; 32: 124–128
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., Graziano S., Chung C., Williams T., Cole B., Kennedy T. Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer. J. Clin. Oncol. 1998; 16: 3316–3322
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., Clark J., Rege V., Papa A., Glantz M., Puthawala Y., Soderberg C., Leone L. A phase I trial of concurrent weekly taxol administered as a 3 hour infusion and radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 1994; 12: 2682–2686
   PubMed Web of Science ®Google Scholar
• Milas L., Hunter N. R., Mason K. A., Milross C. G., Saito Y., Peters L. J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995; 55(16)3564–3568
   PubMed Web of Science ®Google Scholar
• Milas L., Hunter N., Mason K. A., Milross C., Peters L. J. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 1995; 34(3)409–412
   PubMed Web of Science ®Google Scholar
• Geard C. R., Jones J. M., Schiff P. B. Taxol and radiation. J. Natl. Cancer Inst. 1993; 15: 89–94
   Google Scholar
• Choy H., Rodriguez F. F., Koester S., Hilsenbeck S., Von Hoff D. D. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71: 3774–3778
   PubMed Web of Science ®Google Scholar
• Liebmann J., Cook J. A., Fisher J., Teague D., Mitchell J. B. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 1994; 86: 441–446
   PubMed Web of Science ®Google Scholar
• Gupta N., Hu L. J., Deen D. F. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent in combination with ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37: 885–895
   PubMed Web of Science ®Google Scholar
• Kerr J. F.R., Winterford C. M., Harmon B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–2026
   PubMed Web of Science ®Google Scholar
• O'Connor P. M., Jackman J., Bae I., Myers T. G., Fan S., Mutoh M., Scudiero D. A., Monks A., Sausville E. A., Weinstein J. N., Friend S., Fornace A. J., Jr., Kohn K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlation with the growth inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57: 4285–4300
   PubMed Web of Science ®Google Scholar
• Wahl A. F., Donaldson K. L., Fairchild C., Lee F. Y., Foster S. A., Demers G. W., Galloway D. A. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med. 1996; 2: 72–79
   PubMed Web of Science ®Google Scholar
• Safran H., King T., Choy H., Gollerkeri A., Kwakwa H., Lopez F., Cole B., Myers J., Tarpey J., Rosmarin A. p53 Mutations do not predict response to paclitaxel/radiation for non-small cell lung cancer. Cancer 1996; 78: 1209–1216
   Web of Science ®Google Scholar
• Saito Y., Milross C. G., Hittelman W. N., Li D., Jibu T., Peters L. J., Milas L. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int. J. Radiat. Oncol. Biol. Phys. 1997; 38: 623–631
   PubMed Web of Science ®Google Scholar
• Milross C. G., Mason K. A., Hunter N. R., Terry N. H., Patel N., Harada S., Jibu T., Seong J., Milas L. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumors in vivo. Eur. J. Cancer 1997; 33: 1299–1308
   PubMed Web of Science ®Google Scholar
• Mason K. A., Milas L., Peters L. J. Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int. J. Radiat. Oncol. Biol. Phys. 1997; 38: 623–631
   PubMedGoogle Scholar
• Jamal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M. J. Cancer statistics, 2000. CA Cancer J. Clin. 2003; 53: 5–26
   PubMed Web of Science ®Google Scholar
• Hesketh P. J., Clapp R. W., Doos W. G., Spechler S. J. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64: 526–530
   PubMed Web of Science ®Google Scholar
• Blot W. J., Devesa S. S., Kneller R. W., Fraumeni J. F., Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1989; 265: 1287–1289
   Web of Science ®Google Scholar
• Herskovic A., Martz K., al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., Cooper J., Bhardt R., Davis L., Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 1992; 362: 1593–1598
   Google Scholar
• Walsh T. N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T. P. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 1996; 335: 462–467
   PubMed Web of Science ®Google Scholar
• Urba S., Orringer M., Turrisi A., Whyte R., Iannettoni M., Forastiere A. A randomized trial comparing surgery (S) to preoperative concomitant chemoradiation plus surgery in patients (pts) with resectable esophageal cancer CA): updated analysis. Proc. Am. Soc. Clin. Oncol. 1997; 16: 277a, (Abstract 983)
   Google Scholar
• Burmeister B. H., Smithers B. M., Fitzgerald L., Gebski V., Devitt P., Ackland S., Joseph D., Millar J., North J., Walpole E. R., Denham J. W. A randomized phase III trial of preoperative chemoradiation followed by surgery (CR-S) versus surgery alone (S) for localized resectable cancer of the esophagus. Proc. Am. Soc. Clin. Oncol. 2002; 21: 130a, (Abstract 518)
   Google Scholar
• Ajani J. A., Ilson D. H., Dougherty K., Pazdur R., Lynch P. M., Kelsen D. P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. 1994; 86: 1086–1091
   PubMed Web of Science ®Google Scholar
• Kelsen D. P., Ilson D., Wadleigh R., Leichmann L. A phase II multi-center trial of paclitaxel (P) as a weekly one-hour infusion in advanced esophageal cancer (EC). Proc. Am. Soc. Clin. Oncol. 2000; 19: 321a, (Abstract 1266)
   Google Scholar
• Ilson D. H., Ajani J., Bhalla K., Forastiere A., Hung Y., Patel P., Matin L., Donegan J., Pazdur R., Reed C., Kelsen D. P. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J. Clin. Oncol. 1998; 16: 1826–1834
   PubMed Web of Science ®Google Scholar
• Ilson D. H., Forastiere A., Arquette M., Costa F., Heelan R., Hung Y., Kelsen D. P. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 2000; 6: 316–323
   PubMed Web of Science ®Google Scholar
• Van der Gaast A., Kok T. C., Kerkhofs L., Siersema P. D., Tilanus H. W., Splinter T. A. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. Br. J. Cancer 1999; 80: 1052–1057
   PubMed Web of Science ®Google Scholar
• Safran H., Gaissert H., Akerman P., Hesketh P. J., Chen M. H., Moore T., Koness J., Graziano S., Wanebo H. J. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Investig. 2001; 19: 1–7
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Safran H., Clark J., Rege V., Papa A., Glantz M., Puthawala Y., Soderberg C., Leone L. A phase I trial of concurrent weekly taxol administered as a 3 hour infusion and radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 1994; 12: 2682–2686
   PubMed Web of Science ®Google Scholar
• Choy H., Safran H., Akerley W., Graziano S. L., Bogart J. A., Cole B. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin. Cancer Res. 1998; 4: 1931–1936
   PubMed Web of Science ®Google Scholar
• Choy H., Akerley W., Glantz M., Safran H., Graziano S., Chung C. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control 1996; 3: 310–318
   PubMedGoogle Scholar
• Kelsen D., Ilson D., Lipton R., Baylor L., Minsky B. A phase I trial of radiation therapy (RT) plus concurrent fixed dose cisplatin (C) with escalating doses of paclitaxel (P) as a continuous infusion in patients (pts) with localized esophageal cancer (EC). Proc. Am. Soc. Clin. Oncol. 1999; 18: 271a, (Abstract 1039)
   Google Scholar
• Enzinger P., Ilson D., Minsky B., O'Reilly E., Schwartz G., Bains M., Turnbull A., Heelan R., Lipton R., Ginsberg R., Kelsen R. Phase I/II neoadjuvant concurrent 96 hour taxol, cisplatin and radiation therapy, promising toxicity profile and response in localized esophageal cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 271a, (Abstract 1038)
   Google Scholar
• Adelstein D. J., Rice T. W., Rybicki L. A., Larto M. A., Ciezki J., Saxton J., DeCamp M., Vargo J. J., Dummot J. A., Zuccaro G. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J. Clin. Oncol. 2000; 18: 2032–2039
   PubMed Web of Science ®Google Scholar
• Wright C. D., Wain J. C., Lynch T. J., Choi N. C., Grossbard M. L., Carey R. W., Moncure A. C., Grillo H. C., Mathisen C. J. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J. Thorac. Cardiovasc. Surg. 1997; 114: 811–815
   PubMed Web of Science ®Google Scholar
• Gray J. R., Meluch A. A., Kalman L. Neoadjuvant paclitaxel/carboplatin/5-FU/radiaiton therapy for localized esophageal cancer: update of a Minnie Pearl cancer research network phase II trial. Proc. Am. Soc. Clin. Oncol. 1999; 18, (Abstract 1040)
   Google Scholar
• Safran H., DiPetrillo T., Ahmed N., Rathore R., Constantinou M., Ramdin N., Weyman A., Hughes M., MoussaPacha C., Kennedy T., Chak B., Choy H. Neoadjuvant herceptin, paclitaxel, cisplatin and radiation for adenocarcinoma of esophagus: a phase I study. Proc Am. Soc. Clin. Oncol. 2002; 21: 141, (Abstract 560)
   Google Scholar
• MacDonald J. S., Smalley S. R., Benedetti J., Hundahl S. A., Estes N. C., Stemmermann G. N., Haler D. G., Ajani J. A., Gunderson L. L., Jessup J. M., Martenson J. A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001; 345: 725–730
   PubMed Web of Science ®Google Scholar
• Safran H., King T. P., Choy H., Hesketh P. J., Wolf B., Altenhein E., Sikov W., Rosmarin A., Akerley W., Radie-Keane K., Cicchetti G., Lopez F., Bland K., Wanebo H. J. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J. Clin. Oncol. 1997; 15: 901–907
   PubMed Web of Science ®Google Scholar
• Safran H., Wanebo H. J., Hesketh P. J., Akerman P., Ianitti D., Cioffi W., DiPetrillo T., Wolf B., Koness J., McAnaw R., Moore T., Chen M. H., Radie-Kean K. Paclitaxel and concurrent radiation for gastric cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000; 46(4)889–894
   PubMed Web of Science ®Google Scholar
• Schnirer I. I., Komaki R., Yao J. C., Swicher S., Putnam J., Pisters P. W., Roth J. A., Ajani J. A. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am. J. Clin. Oncol. 2001; 24: 91–95
   PubMed Web of Science ®Google Scholar
• Ajani J. A., Komaki R., Putnam J. B., Walsh F., Nesbitt J., Pisters P. W., Lynch P. M., Vaporciyan A., Smythe R., Lahoti S., Raijman I., Swisher S., Martin F. D., Roth J. A. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92: 279–286
   PubMed Web of Science ®Google Scholar
• Evans D. B., Abbruzzese J. L., Rich T. A. Cancer of the pancreas. Cancer: Principles and Practice of Oncology5th Ed., V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 1054–1087
   Google Scholar
• Lillemoe K. D. Current management of pancreatic carcinoma. Ann. Surg. 1995; 221: 133–148
   PubMed Web of Science ®Google Scholar
• Moertel C. G., Frytak S., Hahn R. G., O'Connell M. J., Reitemeier R. J., Rubin J., Schutt A. J., Weiland L. J., Childs D. S., Holbrook M. A., Lavin P. T., Livstone E., Spiro H., Knowlton A., Kalser M., Barkin J., Lessner H., Mann-Kaplan R., Ramming K., Douglas J. O., Jr., Thomas P., Nave H., Bateman J., Lokich J., Brooks J., Chaffey J., Corson J., Zamcheck N., Novak J. W. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the gastrointestinal tumor study group. Cancer 1981; 48: 1705–1710
   PubMed Web of Science ®Google Scholar
• Klaassen D. J., MacIntyre J. M., Catton G. E., Engstrom P. F., Moertel C. G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—An Eastern cooperative oncology group study. J. Clin. Oncol. 1985; 3: 373–378
   PubMed Web of Science ®Google Scholar
• Willett C. G., Safran H., Abrams R. A., Regine W. F., Rich T. A., The Gastrointestinal Committee of the Radiation Therapy Oncology. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56(4 Suppl)31–37, in press
   PubMed Web of Science ®Google Scholar
• Whitehead R. P., Jacobson J., Brown T. D., Taylor S. A., Weiss G. R., Macdonald J. S. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinomas: a southwest oncology group study. J. Clin. Oncol. 1997; 15: 2414–2419
   PubMed Web of Science ®Google Scholar
• Burris H. A., 3rd, Moore M. J., Anderson J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelso R., Dorr F. A., Stephens C. D., Von Hoff D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer—Randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
   PubMed Web of Science ®Google Scholar
• Safran H., Moore T., Iannitti D., DiPetrillo T., Akerman P., Cioffi W., Harrington D., Quirk D., Rathore R., Cruff D., Vakharia J., Vora S., Savarese D., Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 1275–1279
   PubMed Web of Science ®Google Scholar
• Rich T., Harris J., Abrams R., Erickson B., Doherty M., Paradelo J., Small W., Safran H., Wanebo H. A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51(Suppl. 1)26, (Abstract 46)
   Google Scholar
• Lawrence T. Gemcitabine as a radiation sensitizer. Semin. Oncol. 1995; 2: 68–71
   Google Scholar
• Lawrence T. S., Eisbruch A., McGinn C. J., Fields M. T., Shewach D. S. Radiosensitization by gemcitabine. Oncology 1999; 13(Suppl. 5)55–60
   PubMedGoogle Scholar
• Nanfro J. J. Phase I dosing of gemcitabine and concurrent involved field irradiation in patients with localized pancreatic carcinomas. J. Clin. Oncol. 1999; 11: 3692
   Google Scholar
• Kudrimoti M., Regine W., John W., Hanna N., Mohiuddin M. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I/II study. Proc. Am. Soc. Clin. Oncol. 1998; 18: 242, (Abstract 928)
   Google Scholar
• Blackstock A. W., Bernard S. A., Richards F., Eagle K. S., Case L. D., Poole M. E., Savager P. D., Tepper J. E. Phase I trial of twice—weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J. Clin. Oncol. 1999; 17: 2208–2212
   PubMed Web of Science ®Google Scholar
• Blackstock A. W., Tempero M. A., Niedwiecki D., Hollis D. R., Mayer R. J., Tepper J. E. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 2001; 20: 158a, (Abstract 627)
   Google Scholar
• Hoffman J. P., McGinn C. J., Szarka C., Morphis J., Copper H. C., Wilkes J., Nicol S. A phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM for patients with localized, resectable pancreatic adenocarcinoma (PaC). Proc. Am. Soc. Clin. Oncol. 1998; 17: 283a, (Abstract 1090)
   Google Scholar
• McGinn C. J., Zalupski M. M., Shureiqi I., Robertson J. M., Eckhauser F. E., Smith D. C., Brown D., Hejna G., Strawderman M. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2001; 19: 4202–4208
   PubMed Web of Science ®Google Scholar
• Safran H., DiPetrillo T., Iannitti D., Quirk D., Akerman P., Cruff D., Cioffi W., Greenspan N., Shah S., Vakharia J., Ramdin N., Moore T., Rich T. Gemcitabine, paclitaxel and radiation for locally advanced pancreatic cancer: a phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 137–141, in press
   PubMed Web of Science ®Google Scholar